Everything below concerns melanocortin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-18. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
The Shihab dynasty was an Arab family whose members served as the paramount tax farmers and local chiefs of Mount Lebanon from the early 18th to mid-19th century, during Ottoman rule. Their reign began in 1697 after the death of the last Ma'nid chief. In 1697, Amir Ahmad died without an heir, and the Druze notables chose his nephew Bashir al-Shihabi as their new ruler. He was succeeded in 1707 by the young Amir Haydar al-Shihabi, grandson of Amir Ahmad al-Ma'ni. Haydar recognized the authority of the Maronite al-Khazins and the Hubayshis of Kisrawan and Ghazir and treated these two families as equal to the feudalistic Druze families. The Shihab family realized the importance of Maronite rule and power, and they and the Maronites became united in a common interest. The family centralized control over Mount Lebanon, destroying the feudal power of the mostly Druze lords and cultivating the Maronite clergy as an alternative power base of the emirate. During Yusuf Shihab's rule, many members of the Shihab family converted to Christianity and Yusuf also began to rely on the support of the Maronite Christians. On 3 September 1840, Bashir Shihab III, a distant cousin of the once-powerful Emir Bashir Shihab II, was appointed emir of Mount Lebanon by Ottoman Sultan Abdulmejid I. Geographically, the Mount Lebanon Emirate corresponded with the central part of present-day Lebanon, which historically has had a Christian and Druze majority. In practice, the terms "Lebanon" and "Mount Lebanon" tended to be used interchangeably by historians until the formal establishment of the Mandate.
The cells of protists may be bounded only by a cell membrane, or may in addition have a cell wall, or may be covered by a pellicle (in ciliates), a test (in testate amoebae), or a frustule (in diatoms). Some protists such as amoebae may feed on other organisms and ingest food by phagocytosis. Vacuoles known as phagosomes in the cytoplasm may be used to draw in and incorporate the captured particles. Other types of protists are photoautotrophs, providing themselves with energy by photosynthesis. Most single-celled protists are motile, and generate movement with cilia, flagella, or pseudopodia. Ciliates have two different sorts of nuclei: a tiny, diploid micronucleus (the "generative nucleus", which carries the germline of the cell), and a large, ampliploid macronucleus (the "vegetative nucleus", which takes care of general cell regulation.
Modified atmosphere packaging (MAP) is the practice of modifying the composition of the internal atmosphere of a package (commonly food packages, drugs, etc.) in order to improve the shelf life. The need for this technology for food arises from the short shelf life of food products such as meat, fish, poultry, and dairy in the presence of oxygen. In food, oxygen is readily available for lipid oxidation reactions. Oxygen also helps maintain high respiration rates of fresh produce, which contribute to shortened shelf life. From a microbiological aspect, oxygen encourages the growth of aerobic spoilage microorganisms. Therefore, the reduction of oxygen and its replacement with other gases can reduce or delay oxidation reactions and microbiological spoilage. Oxygen scavengers may also be used to reduce browning due to lipid oxidation by halting the auto-oxidative chemical process. MAP achieves changes in the gaseous atmosphere by incorporating different compositions of gases. The modification process generally lowers the amount of oxygen (O2) in the headspace of the package. Oxygen can be replaced with nitrogen (N2), a comparatively inert gas, or carbon dioxide (CO2). A stable atmosphere of gases inside the packaging can be achieved using active techniques, such as gas flushing and compensated vacuum, or passively by designing "breathable" films.
Chinampa – Chinampas, sometimes called "floating gardens," were highly productive agricultural systems developed in the Valley of Mexico. The Aztecs built and used them extensively for agriculture in and around the lakes of the Valley of Mexico. Chocolate – Produced from the seed of the tropical Theobroma cacao tree, cacao was first cultivated by the Olmec of Mesoamerica as early as 1900 BCE. The Maya and Aztec developed chocolate into a frothy ceremonial beverage. Chunkey – a Native American game where a person rolls a hoop covered in a leather strap framework and tries to hit it with spears or arrows. This may have inspired the sport of skeet shooting. Compass (possibly) – the Olmecs are known to have knowledge of magnetism. The discovery of a hematite artifact has led many experts to believe that Olmec invented the compass 1,000 years before the Chinese did, although some still are not convinced. Compulsory education – the Aztec Triple Alliance, which ruled from 1428 to 1521 CE, is considered to be the first state to implement a system of universal compulsory education. Corn beer – brewed in the Andes, it is of pre-Incan origin from the Wari culture. Cornmeal – an unsoaked meal (coarse flour) ground from dried maize. It is a common staple food, and is ground to fine, medium, and coarse consistencies. Cranberries – Native Americans were the first to domesticate and grow cranberries in the north east coast of the United States.
A few psychiatrists (including Sakel) claimed success rates for insulin coma therapy of over 80% in the treatment of schizophrenia. A few others argued that it merely accelerated remission in those patients who were undergoing remission anyway. The consensus at the time was somewhere in between, claiming a success rate of about 50% in patients who had been ill for less than a year (about double the spontaneous remission rate) with no influence on relapse. Sakel suggested the therapy worked by "causing an intensification of the tonus of the parasympathetic end of the autonomic nervous system, by blockading the nerve cell, and by strengthening the anabolic force which induces the restoration of the normal function of the nerve cell and the recovery of the patient." The shock therapies in general had developed on the erroneous premise that epilepsy and schizophrenia rarely occurred in the same patient. The premise was supported by neuropathologic studies that found a dearth of glia in the brains of schizophrenic patients and a surplus of glia in epileptic brains. These observations led the Hungarian neuropsychiatrist Ladislas Meduna to induce seizures in schizophrenic patients with injections of camphor, soon replaced by pentylenetetrazol (Metrazole). Another theory was that patients were somehow "jolted" out of their mental illness. The hypoglycemia (pathologically low glucose levels) that resulted from insulin coma therapy made patients extremely restless, sweaty, and liable to further convulsions and "after-shocks".
Sources: en.wikipedia.org
In the wild they inhabit very soft, acidic waters (pH 4.0 to 4.8) Ideal pH for aquarium is 7.0, but a range of 6.0 to 8.0 is tolerable. They can have a lifespan of as long as ten years, but normally just two to three years in an aquarium. Neon tetras are considered easy to keep in an aquarium of at least 10 US gallons (38 L; 8.3 imp gal) with a temperature range of between 72–76 °F (22–24 °C), a water pH of between 6.0 and 7.0, GH of below 10 dGH and KH of 1–2 dKH, and under 20 ppm of nitrate. They are shoaling fish and must be kept in groups of at least six, but will be more active in groups of eight to 12 or more. Neon tetras are best kept in a densely planted tank to resemble their native Amazon environments.
"Aleutian Islands" . Encyclopædia Britannica. Vol. I (9th ed.). 1878. pp. 479–480. U.S. Coast Pilot 9, Chapter 7, Aleutian Islands U.S. Geological Survey Geographic Names Information System: Aleutian Islands Seattle to Aleutian Island Expedition
Castor oil has been used in cosmetic products, included in creams, and used as a moisturizer. It is often combined with zinc oxide to form an emollient and astringent, zinc and castor oil cream, which is commonly used to treat infants for nappy rash. Hydrogenated castor oil is also known as trihydroxystearin, which is used in cosmetics and personal care systems.
=== Inefficacy === Transfusion inefficacy or insufficient efficacy of a given unit(s) of blood product, while not itself a "complication" per se, can nonetheless indirectly lead to complications – in addition to causing a transfusion to fully or partly fail to achieve its clinical purpose. This can be especially significant for certain patient groups such as critical-care or neonatals. For red blood cells (RBC), by far the most commonly transfused product, poor transfusion efficacy can result from units damaged by the so-called storage lesion – a range of biochemical and biomechanical changes that occur during storage. With red cells, this can decrease viability and ability for tissue oxygenation. Although some of the biochemical changes are reversible after the blood is transfused, the biomechanical changes are less so, and rejuvenation products are not yet able to adequately reverse this phenomenon. There has been controversy about whether a given product unit's age is a factor in transfusion efficacy, specifically about whether "older" blood directly or indirectly increases risks of complications. Studies have not been consistent on answering this question, with some showing that older blood is indeed less effective but with others showing no such difference; these developments are being closely followed by hospital blood bankers – who are the physicians, typically pathologists, who collect and manage inventories of transfusable blood units.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.